课题基金 / 基金详情

CANINE XX SEX REVERSAL

CANINE XX SEX REVERSAL
犬 XX 性别逆转
批准号:
7391974
负责人:
MARK E HASKINS
金额:
$0.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-08-01 至 2007-07-31
关键词:

项目摘要

项目成果

MARK E HASKINS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. For this new project in 2006, we have recently obtained part of the breeding colony of XX sex reversal dogs from Dr. Vicki Meyers-Wallen at Cornell Universtiy. In XX sex reversal, affected individuals have a normal female karyotype (46,XX), and no Y chromosome, yet develop testicular tissue in the gonad. Affected individuals develop testes (XX male) or ovotestes (XX true hermaphrodite). Some XX males have a Y to autosome translocation containing the testis determining gene SRY. However, in SRY-negative XX sex reversal, affected individuals have no Y chromosome and no SRY gene. The frequency of XX males is approximately 1 in 20,000 human births with 10-20% being SRY-negative. The cause of testis induction in the majority of these patients remains unexplained, as a specific genetic defect in XX males has been identified in only one sporadic case and one family with linked cutaneous disease. Additionally, XX true hermaphrodites, which develop ovotestes, occur as siblings of XX males in some families and also within families in which XX males are absent. The mechanism of testis induction in these individuals remains unknown. Characterization of the molecular basis for this disorder would increase our understanding of testis induction and provide diagnostic tests for sex determination disorders. It is difficult to identify such genes in humans since the disorders are uncommon, family sizes are small, and the likelihood of genetic heterogeneity is large. Animal models lack these disadvantages. The canine pedigree segregating the sex reversal trait is strikingly similar to familial SRY-negative XXSR in which XX males and XX true hermaphrodites occur as full siblings. As in humans, canine XX males develop bilateral testes and XX true hermaphrodites develop bilateral ovotestes. Both have a normal female karyotype (78,XX) and Sry is absent, as assayed by Southern blot with a full-length canine Sry probe and polymerase chain reaction with canine specific Sry primers. The causative gene is unknown, but a linked 2 Mb region has been identified in the canine pedigree segregating this trait, using linkage disequilibrium analysis and fine mapping with microsatellite markers. Results to date support a novel etiologic gene as causative in this model, and candidate genes are under investigation. The canine model has several advantages over other animal models. Transgenic mice have been useful to study known genes, but the lack of naturally-occurring mouse models of Sry-negative XXSR suggests that the mouse may not be the model of choice for this particular disorder. Gene expression in normal canine embryonic gonads is similar to that of humans and domestic animals in temporal and spatial expression of key genes involved in sex determination, unlike the mouse. Thus, the canine model is a representative model of mammalian sex determination and has an advantage over other domesticated animals in that it can produce multiple embryos per litter. Furthermore, canine molecular tools (7x canine genome sequence, SNP map) are available to assist positional cloning and to define gene expression patterns during embryonic gonadal sex determination. Thus, the canine model of this disorder is an important model for novel gene discovery and documentation of the molecular mechanism of their role in mammalian sex determination. --
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gene therapy for alpha-mannosidosis
  • 批准号:
    8059579
  • 项目类别:
  • 资助金额:
    $19.72万
  • 财政年份:
    2010
  • 负责人:
    MARK E HASKINS
  • 依托单位:
Gene therapy for alpha-mannosidosis
  • 批准号:
    7877550
  • 项目类别:
  • 资助金额:
    $19.94万
  • 财政年份:
    2010
  • 负责人:
    MARK E HASKINS
  • 依托单位:
GALACTOCEREBROSIDASE DEFICIENCY IN THE DOG - MODEL OF KRABBE DISEASE IN HUMANS
  • 批准号:
    7391958
  • 项目类别:
  • 资助金额:
    $0.07万
  • 财政年份:
    2006
  • 负责人:
    MARK E HASKINS
  • 依托单位:
CANINE MUCOPOLYSACCHARIDOSIS
  • 批准号:
    7391967
  • 项目类别:
  • 资助金额:
    $0.67万
  • 财政年份:
    2006
  • 负责人:
    MARK E HASKINS
  • 依托单位:
国内基金
海外基金
(Tl,K,Rb)yFe2-xX2 (X = S, Se)系统中的部分去 离子实验研究
  • 批准号:
    Y24A040029
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    王杭栋
  • 依托单位:
药物XX通过lncRNAXX作用miRNAXX调控基因XX表达抑制动静脉瘘狭窄的发生发展和机制研究
  • 批准号:
    CSTB2023NSCQ-BHX0188
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2023
  • 负责人:
    郭峰
  • 依托单位:
基于MOFs热解构建薄层碳包覆的BiO1-xX基Z型异质结及其光催化水氧化苯制苯酚反应的研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2019
  • 负责人:
  • 依托单位:
金属-(8-羟基喹啉-5-XX)n/TiO2界面相互作用提升光催化性能的研究
  • 批准号:
    21573039
  • 项目类别:
    面上项目
  • 资助金额:
    66.0万元
  • 批准年份:
    2015
  • 负责人:
    尚庆坤
  • 依托单位: